Literature DB >> 28833569

In vitro and in vivo models to investigate the pathomechanisms and novel treatments for pemphigoid diseases.

Katja Bieber1, Hiroshi Koga2, Wataru Nishie3.   

Abstract

Pemphigoid diseases (PD) are a subgroup of rare acute or chronic autoimmune skin disorders characterized and caused by autoantibodies directed against distinct structural components of the dermal-epidermal junction. Binding of autoantibodies to their targets leads to the formation of blisters and erosions in patients. PDs comprise eight disorders for which the molecular target antigens have been identified. First, we review the available in vitro and ex vivo models for analysis of distinct aspects of the pathogenesis of PDs. This includes the binding of autoantibodies to skin sections, the analysis of blister formation capability and skin complement activation as well as investigation of neutrophil and keratinocyte activation. In addition to this, several animal models of PD have been developed during the last decades. These animal models have greatly contributed to our current understanding of the pathogenesis of PDs. We summarize spontaneously arising PD in animals and the induction of PD by transfer of (auto)antibodies, transfer of (auto)-antigen-specific lymphocytes and by immunization. In combined use, these models allow dissecting all aspects of PD pathogenesis, for example loss of tolerance, autoantibody production and inflammatory skin processes that lead to blister formation. Overall, we aimed to foster translational biomedical research, to deepen our understanding of PD pathogenesis and to develop novel treatments for patients suffering from these life-threatening and difficult-to-treat autoimmune diseases.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  animal model; autoimmune bullous dermatoses; autoimmunity; bullous pemphigoid; epidermolysis bullosa acquisita; pemphigoid disease; skin

Mesh:

Year:  2017        PMID: 28833569     DOI: 10.1111/exd.13415

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  21 in total

Review 1.  Drug Development in Pemphigoid Diseases.

Authors:  Katja Bieber; Ralf J Ludwig
Journal:  Acta Derm Venereol       Date:  2020-02-12       Impact factor: 3.875

2.  Regulatory T Cells Suppress Inflammation and Blistering in Pemphigoid Diseases.

Authors:  Katja Bieber; Shijie Sun; Mareike Witte; Anika Kasprick; Foteini Beltsiou; Martina Behnen; Tamás Laskay; Franziska S Schulze; Elena Pipi; Niklas Reichhelm; René Pagel; Detlef Zillikens; Enno Schmidt; Tim Sparwasser; Kathrin Kalies; Ralf J Ludwig
Journal:  Front Immunol       Date:  2017-11-24       Impact factor: 7.561

3.  Whole-Genome Expression Profiling in Skin Reveals SYK As a Key Regulator of Inflammation in Experimental Epidermolysis Bullosa Acquisita.

Authors:  Unni K Samavedam; Nina Mitschker; Anika Kasprick; Katja Bieber; Enno Schmidt; Tamás Laskay; Andreas Recke; S Goletz; Gestur Vidarsson; Franziska S Schulze; Mikko Armbrust; Katharina Schulze Dieckhoff; Hendri H Pas; Marcel F Jonkman; Kathrin Kalies; Detlef Zillikens; Yask Gupta; Saleh M Ibrahim; Ralf J Ludwig
Journal:  Front Immunol       Date:  2018-02-15       Impact factor: 7.561

4.  Tissue Destruction in Bullous Pemphigoid Can Be Complement Independent and May Be Mitigated by C5aR2.

Authors:  Christian M Karsten; Tina Beckmann; Maike M Holtsche; Jenny Tillmann; Sabrina Tofern; Franziska S Schulze; Eva Nina Heppe; Ralf J Ludwig; Detlef Zillikens; Inke R König; Jörg Köhl; Enno Schmidt
Journal:  Front Immunol       Date:  2018-03-15       Impact factor: 7.561

5.  Mucosal Involvement in Bullous Pemphigoid Is Mostly Associated with Disease Severity and to Absence of Anti-BP230 Autoantibody.

Authors:  Ariane Clapé; Céline Muller; Grégory Gatouillat; Sébastien Le Jan; Coralie Barbe; Bach-Nga Pham; Frank Antonicelli; Philippe Bernard
Journal:  Front Immunol       Date:  2018-03-13       Impact factor: 7.561

6.  The Immunometabolomic Interface Receptor Hydroxycarboxylic Acid Receptor 2 Mediates the Therapeutic Effects of Dimethyl Fumarate in Autoantibody-Induced Skin Inflammation.

Authors:  Melanie Wannick; Julian C Assmann; Jakob F Vielhauer; Stefan Offermanns; Detlef Zillikens; Christian D Sadik; Markus Schwaninger
Journal:  Front Immunol       Date:  2018-08-14       Impact factor: 7.561

7.  Therapeutic Effect of a Novel Phosphatidylinositol-3-Kinase δ Inhibitor in Experimental Epidermolysis Bullosa Acquisita.

Authors:  Hiroshi Koga; Anika Kasprick; Rosa López; Mariona Aulí; Mercè Pont; Núria Godessart; Detlef Zillikens; Katja Bieber; Ralf J Ludwig; Cristina Balagué
Journal:  Front Immunol       Date:  2018-07-12       Impact factor: 7.561

8.  Perspective From the 5th International Pemphigus and Pemphigoid Foundation Scientific Conference.

Authors:  Jinmin Lee; Victoria P Werth; Russell P Hall; Rüdiger Eming; Janet A Fairley; David C Fajgenbaum; Karen E Harman; Marcel F Jonkman; Neil J Korman; Ralf J Ludwig; Dedee F Murrell; Philippe Musette; Haley B Naik; Christian D Sadik; Jun Yamagami; Marc L Yale; Aimee S Payne
Journal:  Front Med (Lausanne)       Date:  2018-11-08

9.  Anti-Type VII Collagen Antibodies Are Identified in a Subpopulation of Bullous Pemphigoid Patients With Relapse.

Authors:  Delphine Giusti; Grégory Gatouillat; Sébastien Le Jan; Julie Plée; Philippe Bernard; Frank Antonicelli; Bach-Nga Pham
Journal:  Front Immunol       Date:  2018-03-21       Impact factor: 7.561

10.  Specific Inhibition of Complement Activation Significantly Ameliorates Autoimmune Blistering Disease in Mice.

Authors:  Sidonia Mihai; Misa Hirose; Yi Wang; Joshua M Thurman; V Michael Holers; B Paul Morgan; Jörg Köhl; Detlef Zillikens; Ralf J Ludwig; Falk Nimmerjahn
Journal:  Front Immunol       Date:  2018-03-16       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.